Navigation Links
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
Date:11/6/2012

st today, November 6, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results and program updates. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (800) 860-2442 for domestic callers, (866) 605-3852 for Canadian callers, or (412) 858-4600 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company's website at www.acelrx.com. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor Relations section of the company's website at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, is currently in Phase 3 clinical development and is designed to solve problems associated with post-operative intravenous patient-controlled analgesia, including side effects of morphine, invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates that have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.  AcelRx has initiated a Phase 2 study for a fourth product candidate, ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from the USAMRMC.
For additional information about AcelRx's clinical programs please visit

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
2. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
3. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
4. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
5. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
7. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
9. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
10. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Nektar Therapeutics (NASDAQ: NKTR ) today ... research scientists at the company,s existing San Francisco ... the UCSF research and medical campus in Mission ... Huntsville, Alabama research site will be relocating to ...
... NEW YORK, March 20, 2012 Reportlinker.com ... is available in its catalogue: ... Global Market Analysis, Size, Share & Forecast ... http://www.reportlinker.com/p0797075/Magnetic-Resonance-Imaging-MRI-Market-Global-Market-Analysis-Size-Share--Forecast-2012---2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging Description ...
Cached Medicine Technology:Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 2Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 3Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 4Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay 5Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 2Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 3Magnetic Resonance Imaging (MRI) Market: Global Market Analysis, Size, Share & Forecast (2012 - 2017) 4
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... , ... has established a strong link between elevated commitment among employees and positive business outcomes. ... Charlotte, NC ... host a webinar titled “Building Workforce Commitment.” The free hour-long webinar will be ...
... ... clients, connecting them with the best-in-class partners around the world, delivering the ultimate experience ... ... a different connotation today than the decades old call center depiction. Clients today ...
... Hospitals ... use” of certified Electronic Medical Record (EMR) systems under the American Recovery and Reinvestment ... ... (ARRA) hospitals and physicians can receive $19 billion in subsidies over five years for ...
... ... SEO firm in 2001 under the name of Anna Tulchinsky Web Consultancy, Joomla Bliss was ... quality or professionalism. The firm is offering several website design + SEO packages tailored specifically ... , ...
... , ... on Interferential mode, is reducing the severity, duration and frequency of pain for many patients ... weeks between treatments. , ... March 9, 2010 -- The Infrex Plus Unit from MedFaxx, when used on Interferential Mode, ...
... ... ... , ... ...
Cached Medicine News:Health News:Morehead Webinar to Discuss Building Workforce Commitment 2Health News:Announcing the Evolution of Provider Placement Methodology – EPIC Connections 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 3Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 2Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 2Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 2Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 3Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 5Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 6Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 7Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 8Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 9
... CRP-HS assay utilizes turbidimetric immunoassay methodology which ... the range of 0.2-28.0 mg/dL. This assay ... to most clinical chemistry analyzers. The Wako ... of precision, linearity, correlation, and sensitivity. Expected ...
... Piccolo is the first compact, broad ... patient testing in any treatment setting. Care ... electrolyte panels with less than one minute ... are comparable in quality to larger, expensive ...
... , The ADVIA 1200 system features a small footprint, ... laboratory. , , Standardization as Part of the ... the same reagents, calibrators and controls as the other ... on the same proven reliability. , , Meets ...
... Stryker BioZip Suture Anchor is a unique double ... BioZip is made from Poly-L Lactic Acid (PLLA) ... Needles are attached to the suture ends for ... arthroscopic repairs. The trocar tip inserter allows insertion ...
Medicine Products: